The global market for preimplantation genetic testing was valued at USD 1.08 billion, and it is anticipated to reach USD 2.49 billion by 2030 with a CAGR of 9.75%.
The process known as preimplantation genetic testing (sometimes called preimplantation genetic diagnosis), embryos created through in vitro fertilization are screened for genetic abnormalities before being implanted in the uterus. Preimplantation genetic testing enables doctors and other medical professionals to identify any genetic flaws in an embryo and selectively implant only healthy embryos in the uterus. It improves the mother's likelihood of giving birth to a child with regular genetic makeup. Preimplantation genetic testing enables individuals to reduce the risk of passing on inherited conditions prevalent in their families to their offspring. The preimplantation procedures consist of various processes, such as harvesting eggs from the mother or an egg donor, which are then fertilized in vitro.
After fertilization, the eggs are subjected to screening procedures that examine them for various genetic abnormalities. Embryos in good health can be frozen and saved for later use, but embryos that are not viable are discarded. The implantation of healthy embryos is done to achieve pregnancy. The selection of a child's gender through preimplantation genetic testing also serves another purpose. On the other hand, this use is currently fraught with several ethical concerns. Individuals who possess a sex-linked genetic condition, are single gene donors, have chromosomal problems, are older women seeking pregnancy, and have a history of repeated abortions are increasingly using preimplantation genetic testing as a therapy option for infertility.
|Market Size||USD 2.49 billion by 2030|
|Fastest Growing Market||Asia-Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
Opportunities for developing advanced diagnostic and treatment approaches are being created due to the growing demand for improved medical services and the expanding discretionary income. Early diagnostic approaches have gained importance in healthcare because of the increased need to prevent physical abnormalities and health problems in neonates. These early diagnostic methods can be used during genetic IVF and other artificial insemination procedures. By evaluating genetic changes in the embryo, preimplantation diagnostic testing can detect inherited disorders such as cystic fibrosis, congenital hearing loss, and thalassemia. In addition, governments and organizations that are not-for-profit aim to improve women's and children's health by raising awareness about the benefits of early genetic illness identification. It will allow for better overall health.
The rise in the incidence of diseases caused by a single gene, mitochondrial, and other gene-related factors has increased the number of people interested in preimplantation diagnostic and screening procedures. According to the data provided by the Florida Department of Health, a congenital disability is identified in around one in every 28 newborns born in Florida each year. Preimplantation genetic diagnosis (PGD) is used for a successful pregnancy before IVF. PGD may be utilized during an IVF cycle for women who have experienced unsuccessful pregnancies or previously carried a child affected by chromosomal abnormalities. PGD can help couples risk passing on a genetic illness to their children.
As a result of the high frequency of infertility among practically all women and genetic problems caused by the intake of chemically processed foods, there is a multitude of potential for the market to flourish. As a result, preimplantation genetic treatment is in high demand, as it can reduce the risk that an embryo will be afflicted by genetic disorders or other faults and help to successfully birth a child with optimal health. Therefore, preimplantation genetic testing opens many doors to the possibility of having infants with predetermined genetic modifications. It presents a chance to do genetic testing before the implantation of an embryo. That causes the market to react in a highly positive manner.
Despite the many positive aspects associated with preimplantation genetic testing, the sector's expansion is hampered by several obstacles. The ethical acceptability of PGT services and the legal controls exercised by public entities are among the most significant obstacles that hinder the adoption rate of PGT services. In addition, some clinicians and academics are sceptical regarding the effectiveness of these procedures. Additionally, even though preimplantation genetic diagnosis necessitates the deliberate creation of a deformed human embryo and subsequent termination of its life, very few people believe this practice is morally reprehensible. On the other hand, other organizations advocate for adults to be absolved of guilt when passing hereditary illnesses on to their children and grandkids.
The preimplantation genetic testing market is classified into four different regions: North America, Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa.
North America was the region that accounted for the most significant revenue share in the global preimplantation genetics diagnosis (PGD) market in 2021, which led to its emergence as the leading region in this market. That's because the amount of money spent on health care and the number of people living in the country is rising. As of 2019, the United States Department of Health and Human Services reports that 489 fertility clinics offer assisted reproductive technology (ART) solutions. The highest rate of births caused by assisted reproductive technology can be found in several states, including Massachusetts, Columbia, and New Jersey. In addition, a growing awareness of the importance of healthy embryos in countries with lower living standards is anticipated to provide a financial opportunity for preimplantation genetic diagnosis.
The European Union (EU) region is the second-largest market. Its success can be ascribed to lifestyle changes and high infertility rates, particularly in the United Kingdom, Germany, and Spain.
The market in Asia and the Pacific is anticipated to expand the fastest throughout the projection period, even though it is far less significant than the top two regions. It can be ascribed to the vast population and high fertility rates connected with the shift in lifestyles that triggered the demand for the utilization of preimplantation genetic testing procedures. China, India, and Japan are the leading markets in the APAC area.
Brazil, South Africa, and Saudi Arabia are now leading the market segment in countries located in Latin America and the middle east. It can be linked to these countries' more lavish spending on their health care systems.
The global market for preimplantation genetic testing is segmented based on procedure type, product & service, application, end-users and region. Further, each segment is divided into sub-segments. Based on procedure type, the market is broken down into Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.
Based on product & service, the market is divided into Comparative Genomic Hybridization, Single-Nucleotide Polymorphism, Next-Generation Sequencing, Polymerase Chain Reaction, Validation Biomarkers and Fluorescence in Situ Hybridization. The next-generation sequencing segment dominated the market. It can be justified by the stringent conditions that must be met when sequencing the genomes of newborn babies and the need for adequate fertilization when in vitro fertilization is used.
The application-based segment is divided into Single Gene Disorders, X-Linked Disorders, Aneuploidy, Structural Chromosomal Abnormalities and HLA Typing. The aneuploidy segment dominated the market. Preimplantation genetic testing for aneuploidy has been suggested as a way to find whole chromosomal aneuploidy before the transfer. This could increase the number of live births and decrease the number of early miscarriages. Array comparative genomic hybridization and next-generation sequencing techniques have been used to expand preimplantation genetic testing for aneuploidy, including evaluating all chromosomes.
According to end-users, the market is divided into Hospitals, Diagnostic Labs and Service Providers, Maternity Centres & Fertility Clinics and Research Laboratories & Academic Institutes. The maternity centres & fertility clinics segment dominated the market. It can be attributable to the in-clinic treatments and therapies employing preimplantation genetic testing methods.
April 2022, Illumina Provides Financial Assistance to a Preeminent German Hospital to Improve the Rate of Genetic Disease Diagnosis in Seriously Ill Children.
April 2022, Natera, Inc. is a global pioneer in cell-free DNA testing. It has revealed the outcomes of large, real-world research demonstrating a high yield rate for positive genetic findings using the company's RenasightTM test in patients with chronic kidney disease (CKD).